Rosen Quoted on Gilead Sciences' Lost Bid for NCE Exclusivity

18 April 2014 FDA Week News

FDA Week

Partner David Rosen was quoted in an article published in FDA Week on April 18, 2014, titled “FDA Argument For 5-Year NCE Exclusivity Denial Unfounded, Gilead Says.” The article explains the appeal by Gilead Sciences, a manufacturer of one of three drug-drug combination products, asking the Federal Drug Administration (FDA) to reconsider its decision to prospectively change its new chemical entities policies for other combination drugs. Rosen was quoted saying, “One thing you can appreciate is FDA is very considered in its decision-making process at this time.”

Related Services


When Birds Finally Find a Nest
17 September 2019
Dashboard Insights
DHS Moves Closer to Launching its H-1B Cap Registration System
16 September 2019
Labor & Employment Law Perspectives
Be Aware of Potential Legal Restrictions When Implementing a Workplace Weapons Policy
16 September 2019
Labor & Employment Law Perspectives
EEO-1 Component 2 Filing Deadline is Just Days Away – But Employers May Be Off the Hook Next Year
16 September 2019
Labor & Employment Law Perspectives
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.
CTeL Telehealth Fall Summit 2019
04-06 December 2019
Washington, D.C.